Polskie Stowarzyszenie HR (KRS 0000738519, NIP 1182176425) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. POLSKIE STOWARZYSZENIE HR operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since June 29, 2018. POLSKIE STOWARZYSZENIE HR's most recently reported net revenue was 22.8 K PLN for 2023.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Polskie Stowarzyszenie HR
Identity
- Name
- Polskie Stowarzyszenie HR
- Legal form
- STOWARZYSZENIE
- Founded
- June 29, 2018
- Registry status as of
- June 29, 2026
- Latest entry
- June 29, 2026
- Founding act
- 07.02.2018 R. 13.06.2018 R. - ZMIANA STATUTU.
Articles of association history (4)
- February 7, 2018: 07.02.2018 R. 13.06.2018 R. - ZMIANA STATUTU.
- 28 MARCA 2019 R. ZMIANA §22 PKT 3 STATUTU STOWARZYSZENIA
- 09 MAJA 2019 R. ZMIANA § 20 UST.7 STATUTU STOWARZYSZENIA I PRZYJĘCIE TEKSTU JEDNOLITEGO
- 28 LISTOPADA 2024 R. ZMIENIONO § 10 UST. 1 LIT. B; § 11 UST. 1 LIT. B; § 12 UST. 1 LIT. A; § 15; § 16; § 20 UST. 3; § 20 UST. 8; W § 20 PO UST. 9 DODANO NOWE UST. 10-13; W § 20 DOTYCHCZASOWE UST. 10 ORAZ 11 OTRZYMAŁY ODPOWIEDNIO NUMERY 14 ORAZ 15; ZMIENIONO § 21 UST. 4.
Activities
Main activity
72.20.ZResearch and experimental development on social sciences and humanities
Other activities
Address and contact
- Address
- UL. JANA KOCHANOWSKIEGO, 49, 01-864, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-71933-28151-RJSCF-33
Risk and payment profile - Polskie Stowarzyszenie HR
Credibility rating
57.6 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
0
0/8 yrs
Board changes
7
7/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2023
Current: C (58/100)
Trend: improving (+4.5 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2023
Current: 7.0 K PLN
Safe: 3.2 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Polskie Stowarzyszenie HR
Founded
June 29, 2018
8 years in operation
Legal form
STOWARZYSZENIE
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Share capital
N/A
Shareholders
N/A
Board
7 people
Sup. board: 5
Filed years
3 years
2018–2023
Registry entries
28
latest: June 29, 2026
Revenue
22.8 K PLN
2023
Net profit
2.5 K PLN
2023
Assets
73.4 K PLN
2023
Equity
25.6 K PLN
2023
EBITDA
N/A
2023
no depreciation data
Valuation
15.4 K PLN
Medium confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Polskie Stowarzyszenie HR.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
